DisopyramideDisopyramide, classified as a type I antiarrhythmic (i.e., a sodium channel blocker) is a potent negative inotrope. It has been used to decrease left ventricular outflow tract obstruction in obstructive HCM since first reports in the early 1980’s. Until recently it was not known whether...
Multiscale modeling of left ventricleIn silico clinical trials are the future of medicine and virtual testing and simulation are the future of medical engineering. The use of a computational platform can reduce the costs and time required for developing new models of medical devices and...
Effect of Myosin Isoforms from Mouse to HumanTo understand how pathology-induced changes in contractile protein isoforms modulate cardiac muscle function, it is necessary to quantify the temporal-mechanical properties of contractions that occur under various conditions. Pathological responses are much easier to study in animal model...
L48Q and I61QA challenge in experimental studies of muscle diseases is accounting for the effect of variable mutation incorporation into myofilaments. In this study, we used a spatially explicit computational model MUSICO Fiber, informed by experimental data from transgenic mice expressing one of two mutations...
MavacamtenMavacamten (MYK-461) was recently approved by FDA as an allosteric inhibitor of sarcomeric myosins since it had been successfully used in clinical trials for treatment of obstructive HCM. Mavacamten negative inotropic action is likely mediated by the shift of detached motor heads towards auto inhibited...
We are excited to announce FilamenTech’s participation in a new scientific project called “Analysis Tools for Fiber Diffraction of Muscle” (R01GM144555), supported by National Institute of General Medical Sciences of the National Institutes of Health. Principal investigator is Thomas C. Irving from Illinois Institute of...
FilamenTech has recently started a collaboration with prof. Aleksandar G. Ostrogorsky from Illinois Institute of Technology, Chicago, IL, USA on performing simulations and data analysis for the optimization of the DiGS experiments conducted on Earth and at the ISS (International Space Station) within the project:...
Over the last 4 years, FilamenTech’s co-founders prof. Srboljub Mijailovich and Momcilo Prodanovic, along with FilamenTech’s scientific board members were involved in the project called “SilicoFCM - In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy” (No 777204),...